These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

2442 related articles for article (PubMed ID: 11786451)

  • 41. Thienopyridines or aspirin to prevent stroke and other serious vascular events in patients at high risk of vascular disease? A systematic review of the evidence from randomized trials.
    Hankey GJ; Sudlow CL; Dunbabin DW
    Stroke; 2000 Jul; 31(7):1779-84. PubMed ID: 10884487
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Comparative Efficacy and Safety of Different Antiplatelet Agents for Prevention of Major Cardiovascular Events and Leg Amputations in Patients with Peripheral Arterial Disease: A Systematic Review and Network Meta-Analysis.
    Katsanos K; Spiliopoulos S; Saha P; Diamantopoulos A; Karunanithy N; Krokidis M; Modarai B; Karnabatidis D
    PLoS One; 2015; 10(8):e0135692. PubMed ID: 26274912
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Net clinical benefit of adding clopidogrel to aspirin therapy in patients with atrial fibrillation for whom vitamin K antagonists are unsuitable.
    Connolly SJ; Eikelboom JW; Ng J; Hirsh J; Yusuf S; Pogue J; de Caterina R; Hohnloser S; Hart RG;
    Ann Intern Med; 2011 Nov; 155(9):579-86. PubMed ID: 22041946
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Long-term oral platelet glycoprotein IIb/IIIa receptor antagonism with sibrafiban after acute coronary syndromes: study design of the sibrafiban versus aspirin to yield maximum protection from ischemic heart events post-acute coronary syndromes (SYMPHONY) trial. Symphony Steering Committee.
    Newby LK
    Am Heart J; 1999 Aug; 138(2 Pt 1):210-8. PubMed ID: 10426831
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Aspirin plus dipyridamole versus aspirin alone after cerebral ischaemia of arterial origin (ESPRIT): randomised controlled trial.
    ; Halkes PH; van Gijn J; Kappelle LJ; Koudstaal PJ; Algra A
    Lancet; 2006 May; 367(9523):1665-73. PubMed ID: 16714187
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Early and sustained dual oral antiplatelet therapy following percutaneous coronary intervention: a randomized controlled trial.
    Steinhubl SR; Berger PB; Mann JT; Fry ET; DeLago A; Wilmer C; Topol EJ;
    JAMA; 2002 Nov; 288(19):2411-20. PubMed ID: 12435254
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Monotherapy with a P2Y
    Chiarito M; Sanz-Sánchez J; Cannata F; Cao D; Sturla M; Panico C; Godino C; Regazzoli D; Reimers B; De Caterina R; Condorelli G; Ferrante G; Stefanini GG
    Lancet; 2020 May; 395(10235):1487-1495. PubMed ID: 32386592
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Adenosine-diphosphate (ADP) receptor antagonists for the prevention of cardiovascular disease in type 2 diabetes mellitus.
    Valentine N; Van de Laar FA; van Driel ML
    Cochrane Database Syst Rev; 2012 Nov; 11(11):CD005449. PubMed ID: 23152231
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Systematic review of antiplatelet therapy for the prevention of myocardial infarction, stroke or vascular death in patients with peripheral vascular disease.
    Robless P; Mikhailidis DP; Stansby G
    Br J Surg; 2001 Jun; 88(6):787-800. PubMed ID: 11412247
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Rivaroxaban with or without aspirin in patients with stable coronary artery disease: an international, randomised, double-blind, placebo-controlled trial.
    Connolly SJ; Eikelboom JW; Bosch J; Dagenais G; Dyal L; Lanas F; Metsarinne K; O'Donnell M; Dans AL; Ha JW; Parkhomenko AN; Avezum AA; Lonn E; Lisheng L; Torp-Pedersen C; Widimsky P; Maggioni AP; Felix C; Keltai K; Hori M; Yusoff K; Guzik TJ; Bhatt DL; Branch KRH; Cook Bruns N; Berkowitz SD; Anand SS; Varigos JD; Fox KAA; Yusuf S;
    Lancet; 2018 Jan; 391(10117):205-218. PubMed ID: 29132879
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Clopidogrel plus aspirin versus aspirin alone for acute minor ischaemic stroke or high risk transient ischaemic attack: systematic review and meta-analysis.
    Hao Q; Tampi M; O'Donnell M; Foroutan F; Siemieniuk RA; Guyatt G
    BMJ; 2018 Dec; 363():k5108. PubMed ID: 30563866
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Design of the blockade of the glycoprotein IIb/IIIa receptor to avoid vascular occlusion (BRAVO) trial.
    Topol EJ; Easton JD; Amarenco P; Califf R; Harrington R; Graffagnino C; Davis S; Diener HC; Ferguson J; Fitzgerald D; Shuaib A; Koudstaal PJ; Theroux P; Van de Werf F; Willerson JT; Chan R; Samuels R; Ilson B; Granett J
    Am Heart J; 2000 Jun; 139(6):927-33. PubMed ID: 10827369
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Medium intensity oral anticoagulants versus aspirin after cerebral ischaemia of arterial origin (ESPRIT): a randomised controlled trial.
    ; Halkes PH; van Gijn J; Kappelle LJ; Koudstaal PJ; Algra A
    Lancet Neurol; 2007 Feb; 6(2):115-24. PubMed ID: 17239798
    [TBL] [Abstract][Full Text] [Related]  

  • 54. [Prevention of major ischemic events in lower limb arterial disease: does aspirin play a role?].
    Lechat P; Priollet P
    J Mal Vasc; 2006 Jul; 31(3):129-34. PubMed ID: 16840949
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Network meta-analysis: simultaneous meta-analysis of common antiplatelet regimens after transient ischaemic attack or stroke.
    Thijs V; Lemmens R; Fieuws S
    Eur Heart J; 2008 May; 29(9):1086-92. PubMed ID: 18349026
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Antiplatelet versus anticoagulation treatment for patients with heart failure in sinus rhythm.
    Shantsila E; Lip GY
    Cochrane Database Syst Rev; 2016 Sep; 9(9):CD003333. PubMed ID: 27629776
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Antiplatelet therapy for preventing stroke in patients with non-valvular atrial fibrillation and no previous history of stroke or transient ischemic attacks.
    Aguilar M; Hart R
    Cochrane Database Syst Rev; 2005 Oct; (4):CD001925. PubMed ID: 16235290
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Dual antiplatelet therapy using cilostazol for secondary prevention in patients with high-risk ischaemic stroke in Japan: a multicentre, open-label, randomised controlled trial.
    Toyoda K; Uchiyama S; Yamaguchi T; Easton JD; Kimura K; Hoshino H; Sakai N; Okada Y; Tanaka K; Origasa H; Naritomi H; Houkin K; Yamaguchi K; Isobe M; Minematsu K;
    Lancet Neurol; 2019 Jun; 18(6):539-548. PubMed ID: 31122494
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Validity of composite outcomes in meta-analyses of stroke prevention trials: the case of aspirin.
    McGrath E; O'Conghaile A; Eikelboom JW; Dinneen SF; Oczkowski C; O'Donnell MJ
    Cerebrovasc Dis; 2011; 32(1):22-7. PubMed ID: 21576939
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Antiplatelet drugs.
    Hankey GJ; Eikelboom JW
    Med J Aust; 2003 Jun; 178(11):568-74. PubMed ID: 12765506
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 123.